Contrasting STERIS (NYSE:STE) and Microbot Medical (NASDAQ:MBOT)

Microbot Medical (NASDAQ:MBOT) and STERIS (NYSE:STE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings.

Valuation & Earnings

This table compares Microbot Medical and STERIS”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14 million	($0.26)	-6.85
STERIS	$5.94 billion	3.41	$782.30 million	$7.93	26.17

STERIS has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 4.7% of Microbot Medical shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Microbot Medical and STERIS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
STERIS	13.18%	14.15%	9.52%

Volatility and Risk

Microbot Medical has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, STERIS has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Microbot Medical and STERIS, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1	1	2	1	2.60
STERIS	0	1	3	0	2.75

Microbot Medical currently has a consensus target price of $6.63, suggesting a potential upside of 272.19%. STERIS has a consensus target price of $278.00, suggesting a potential upside of 33.98%. Given Microbot Medical’s higher possible upside, equities analysts plainly believe Microbot Medical is more favorable than STERIS.

Summary

STERIS beats Microbot Medical on 10 of the 14 factors compared between the two stocks.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.